hero image

Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors

January 10, 2008 Investor Relations

Former Tufts Health Plan President & CEO to Bring Extensive Healthcare Experience to Board

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced the appointment of Nancy L. Leaming to its Board of Directors.

“I’m very pleased that Nancy Leaming is joining our Board of Directors,” said Bruce Ross, Biogen Idec’s Chairman. “With extensive experience in the healthcare sector, Nancy has the proven business and leadership skills to help Biogen Idec drive our strategic plan forward in the years ahead.”

For twenty years, Leaming, 60, served in several executive positions at Tufts Health Plan, including President and CEO (2003 – 2005), President and Chief Operating Officer (1997-2003) and Chief Operating Officer (1986-1997). Leaming successfully led the managed care company to become a nationally recognized leader in its field, creating a strategic vision and strong corporate culture defined by product innovation, service excellence, quality and patient safety.

Leaming has served in various capacities on both commercial and non-profit boards. She is currently a member of the boards of directors at Hologic Inc., where she chairs the Audit Committee, Edgewater Technology Inc., the Massachusetts Taxpayers Foundation and the American Red Cross of Massachusetts.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

Biogen Idec Media Contact:
Naomi Aoki, 617-914-6524
Director, Public Affairs
or
Biogen Idec Investor Relations Contact:
Eric Hoffman, PhD, 617-679-2812
Associate Director, Investor Relations

thumb
May 10, 2021
Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

Collaboration aims to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disorders Capsigen’s screening technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across

thumb
April 28, 2021
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of